RU2007130558A - Производные аминофенола в качестве селективных модуляторов андрогеновых рецепторов - Google Patents
Производные аминофенола в качестве селективных модуляторов андрогеновых рецепторов Download PDFInfo
- Publication number
- RU2007130558A RU2007130558A RU2007130558/04A RU2007130558A RU2007130558A RU 2007130558 A RU2007130558 A RU 2007130558A RU 2007130558/04 A RU2007130558/04 A RU 2007130558/04A RU 2007130558 A RU2007130558 A RU 2007130558A RU 2007130558 A RU2007130558 A RU 2007130558A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- azabicyclo
- endo
- group
- substituted
- Prior art date
Links
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 title 1
- 239000000849 selective androgen receptor modulator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 29
- -1 cyano, hydroxy Chemical group 0.000 claims 16
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 208000030159 metabolic disease Diseases 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
- 210000003205 muscle Anatomy 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 229910005965 SO 2 Inorganic materials 0.000 claims 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 4
- 230000037182 bone density Effects 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 230000001568 sexual effect Effects 0.000 claims 4
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 208000005494 xerophthalmia Diseases 0.000 claims 4
- 208000019022 Mood disease Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 206010013883 Dwarfism Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000004483 Dyspareunia Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010053759 Growth retardation Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010058359 Hypogonadism Diseases 0.000 claims 2
- 208000030663 Libido disease Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000007466 Male Infertility Diseases 0.000 claims 2
- 208000002720 Malnutrition Diseases 0.000 claims 2
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 102000001307 androgen receptors Human genes 0.000 claims 2
- 108010080146 androgen receptors Proteins 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 230000037007 arousal Effects 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 231100000001 growth retardation Toxicity 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 238000002657 hormone replacement therapy Methods 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 230000001071 malnutrition Effects 0.000 claims 2
- 235000000824 malnutrition Nutrition 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 2
- 230000008447 perception Effects 0.000 claims 2
- 230000010412 perfusion Effects 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 208000001076 sarcopenia Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000021595 spermatogenesis Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 229960003604 testosterone Drugs 0.000 claims 2
- 206010046947 vaginismus Diseases 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000013043 chemical agent Substances 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 238000011474 orchiectomy Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64284105P | 2005-01-10 | 2005-01-10 | |
| US60/642,841 | 2005-01-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007130558A true RU2007130558A (ru) | 2009-02-20 |
Family
ID=36591321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007130558/04A RU2007130558A (ru) | 2005-01-10 | 2006-01-09 | Производные аминофенола в качестве селективных модуляторов андрогеновых рецепторов |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7585877B2 (enExample) |
| EP (1) | EP1836202B1 (enExample) |
| JP (1) | JP5203712B2 (enExample) |
| KR (1) | KR20070112775A (enExample) |
| CN (1) | CN101119993B (enExample) |
| AU (1) | AU2006205066B2 (enExample) |
| CA (1) | CA2594340C (enExample) |
| MX (1) | MX2007008334A (enExample) |
| NZ (1) | NZ555974A (enExample) |
| RU (1) | RU2007130558A (enExample) |
| WO (1) | WO2006076317A2 (enExample) |
| ZA (1) | ZA200705458B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070004679A1 (en) * | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
| US20060173037A1 (en) * | 2005-01-10 | 2006-08-03 | Nathalie Schlienger | Aminophenyl derivatives as selective androgen receptor modulators |
| NZ555974A (en) | 2005-01-10 | 2010-11-26 | Acadia Pharm Inc | Aminophenyl derivatives as selective androgen receptor modulators |
| WO2007015567A1 (ja) * | 2005-08-01 | 2007-02-08 | Takeda Pharmaceutical Company Limited | 環状アミン化合物 |
| NZ573735A (en) | 2006-05-19 | 2011-10-28 | Abbott Lab | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
| CA2670976C (en) | 2006-11-30 | 2015-01-27 | Atsushi Hasuoka | Cyclic amine compound |
| MY159910A (en) | 2007-08-07 | 2017-02-15 | Takeda Pharmaceuticals Co | Pyrrolidin-2-one derivatives as androgen receptor modulator |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| BRPI0907844B8 (pt) | 2008-02-22 | 2021-05-25 | Radius Health Inc | compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos |
| JP5964756B2 (ja) | 2010-02-04 | 2016-08-03 | ラジウス ヘルス，インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
| PL2568806T3 (pl) | 2010-05-12 | 2017-03-31 | Radius Health, Inc. | Schematy lecznicze |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| AU2011312490B2 (en) | 2010-09-28 | 2015-06-25 | Radius Pharmaceuticals, Inc. | Selective androgen receptor modulators |
| EP2736910B1 (en) | 2011-07-27 | 2015-08-19 | Novartis AG | Pyrazoline derivatives and their use as selective androgen receptor modulators |
| WO2014125121A1 (en) | 2013-02-18 | 2014-08-21 | Acadia Pharmaceuticals Inc. | Compounds and compositions for treating neurodegenerative diseases |
| EP2968365A1 (en) * | 2013-03-15 | 2016-01-20 | Malhotra, Raman | Systemic administration of androgen in treating dry eye syndrome |
| ES2939940T3 (es) | 2014-03-28 | 2023-04-28 | Univ Duke | Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| PT3150599T (pt) | 2014-05-29 | 2018-12-28 | Taiho Pharmaceutical Co Ltd | Novo composto de tetrahidropiridopirimidina ou sal do mesmo |
| US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| RU2689988C2 (ru) * | 2015-04-21 | 2019-05-30 | Джи Ти Икс, ИНК. | Селективные лиганды-разрушители андрогенных рецепторов (sard) и способы их применения |
| US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
| EP3381916B1 (en) | 2015-11-27 | 2020-04-15 | Taiho Pharmaceutical Co., Ltd. | Condensed pyrimidine compound or salt thereof |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| WO2017223115A1 (en) | 2016-06-22 | 2017-12-28 | Radius Health, Inc. | Ar+ breast cancer treatment methods |
| EP3565542B1 (en) | 2017-01-05 | 2024-04-10 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
| BR112020023136A2 (pt) | 2018-05-14 | 2021-02-09 | Nuvation Bio Inc. | compostos de alvo de receptor de hormônio nuclear anticâncer |
| SG11202013177WA (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals Inc | Polymorphic forms of rad 1901-2hcl |
| US12202815B2 (en) | 2018-09-05 | 2025-01-21 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US12441745B2 (en) | 2019-02-12 | 2025-10-14 | Radius Pharmaceuticals, Inc. | Processes and compounds |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4313991A1 (en) | 2021-03-23 | 2024-02-07 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2022212631A1 (en) * | 2021-03-31 | 2022-10-06 | Taiho Pharmaceutical Co., Ltd. | Treatment of patients metastatic castration-resistant prostate cancer with an androgen receptor antagonist |
| WO2022235585A1 (en) | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL140992B (nl) | 1963-07-06 | 1974-01-15 | Kalle Ag | Kopieermateriaal, dat een lichtgevoelig diazoniumzout bevat en werkwijze voor het bereiden van dat zout. |
| DE3100535A1 (de) | 1981-01-10 | 1982-08-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | "neue carbonsaeure-derivate, ihre herstellung und ihre verwendung als arzneimittel" |
| US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| IL110298A (en) | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| DE4404198A1 (de) | 1994-02-10 | 1995-08-17 | Henkel Kgaa | 2-Fluor-6-nitroaniline |
| US5507798A (en) * | 1994-09-14 | 1996-04-16 | United States Surgical Corporation | Surgical needle-suture attachment for controlled suture release |
| BR9509673A (pt) | 1994-11-15 | 1997-09-30 | Upjohn Co | Compostos e uso dos mesmos |
| GB9510459D0 (en) | 1995-05-24 | 1995-07-19 | Zeneca Ltd | Bicyclic amines |
| AT403803B (de) * | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| US6569896B2 (en) | 2000-08-24 | 2003-05-27 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
| JP2002516825A (ja) | 1998-05-26 | 2002-06-11 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 電荷移動蛍光プローブを作製するためのプローブ |
| EP1082323A2 (en) | 1998-06-05 | 2001-03-14 | AstraZeneca UK Limited | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them |
| WO2000017163A1 (en) | 1998-09-22 | 2000-03-30 | Yamanouchi Pharmaceutical Co., Ltd. | Cyanophenyl derivatives |
| DE69914935T2 (de) * | 1998-11-27 | 2009-10-01 | Neurosearch A/S | 8-azabicyclo[3.2.1]okt-2-en- und -oktanderivate |
| JP2002088073A (ja) * | 2000-09-08 | 2002-03-27 | Yamanouchi Pharmaceut Co Ltd | 抗アンドロゲン剤 |
| US7214690B2 (en) | 2001-02-23 | 2007-05-08 | Ligand Pharmaceuticals Incorporated | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods |
| US20040087548A1 (en) * | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| WO2003011824A1 (en) | 2001-07-31 | 2003-02-13 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| WO2003016251A1 (en) | 2001-08-16 | 2003-02-27 | Ube Industries, Ltd. | Process for preparation of cyclododecanone |
| TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
| US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| NZ538713A (en) | 2002-08-12 | 2007-01-26 | Takeda Chemical Industries Ltd | Fused benzene derivative and use |
| US6933311B2 (en) * | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| DE10322108B4 (de) * | 2003-05-09 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit |
| WO2005000795A2 (en) | 2003-06-10 | 2005-01-06 | Smithkline Beecham Corporation | Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators |
| US20050113576A1 (en) * | 2003-08-05 | 2005-05-26 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| CA2545048A1 (en) | 2003-11-20 | 2005-06-02 | Warner-Lambert Company Llc | Androgen receptor modulators |
| US8519158B2 (en) | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| EP1756101A2 (en) | 2004-05-17 | 2007-02-28 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| WO2006013887A1 (ja) | 2004-08-03 | 2006-02-09 | Chugai Seiyaku Kabushiki Kaisha | 新規イミダゾリジン誘導体 |
| US20060173037A1 (en) * | 2005-01-10 | 2006-08-03 | Nathalie Schlienger | Aminophenyl derivatives as selective androgen receptor modulators |
| NZ555974A (en) | 2005-01-10 | 2010-11-26 | Acadia Pharm Inc | Aminophenyl derivatives as selective androgen receptor modulators |
-
2006
- 2006-01-09 NZ NZ555974A patent/NZ555974A/en not_active IP Right Cessation
- 2006-01-09 WO PCT/US2006/000733 patent/WO2006076317A2/en not_active Ceased
- 2006-01-09 US US11/329,267 patent/US7585877B2/en not_active Expired - Fee Related
- 2006-01-09 JP JP2007550547A patent/JP5203712B2/ja not_active Expired - Fee Related
- 2006-01-09 CA CA2594340A patent/CA2594340C/en not_active Expired - Fee Related
- 2006-01-09 ZA ZA200705458A patent/ZA200705458B/xx unknown
- 2006-01-09 RU RU2007130558/04A patent/RU2007130558A/ru not_active Application Discontinuation
- 2006-01-09 EP EP06733660.2A patent/EP1836202B1/en not_active Expired - Lifetime
- 2006-01-09 MX MX2007008334A patent/MX2007008334A/es not_active Application Discontinuation
- 2006-01-09 AU AU2006205066A patent/AU2006205066B2/en not_active Ceased
- 2006-01-09 KR KR1020077018305A patent/KR20070112775A/ko not_active Withdrawn
- 2006-01-09 CN CN200680002003.2A patent/CN101119993B/zh not_active Expired - Fee Related
-
2009
- 2009-06-30 US US12/495,514 patent/US20090270449A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070112775A (ko) | 2007-11-27 |
| WO2006076317A2 (en) | 2006-07-20 |
| US7585877B2 (en) | 2009-09-08 |
| NZ555974A (en) | 2010-11-26 |
| US20060160845A1 (en) | 2006-07-20 |
| AU2006205066A1 (en) | 2006-07-20 |
| JP2008526888A (ja) | 2008-07-24 |
| AU2006205066B2 (en) | 2012-05-17 |
| MX2007008334A (es) | 2007-09-11 |
| ZA200705458B (en) | 2008-12-31 |
| EP1836202A2 (en) | 2007-09-26 |
| CA2594340A1 (en) | 2006-07-20 |
| CA2594340C (en) | 2015-11-10 |
| EP1836202B1 (en) | 2016-12-21 |
| US20090270449A1 (en) | 2009-10-29 |
| CN101119993B (zh) | 2015-03-04 |
| WO2006076317A9 (en) | 2007-09-27 |
| JP5203712B2 (ja) | 2013-06-05 |
| CN101119993A (zh) | 2008-02-06 |
| WO2006076317A3 (en) | 2006-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526888A5 (enExample) | ||
| AU2014223973B2 (en) | Amide compounds for the treatment of HIV | |
| CA3089590C (en) | Pyridine derivatives and their use for treating hiv infection | |
| AU2016338118B2 (en) | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| RU2448096C2 (ru) | Диарилгидантоины | |
| RU2006144863A (ru) | Модуляторы андрогеновых рецепторов и способ лечения заболеваний с их помощью | |
| AU2014348518B2 (en) | Azepane derivatives and methods of treating hepatitis B infections | |
| JP5726998B2 (ja) | 核内受容体結合剤 | |
| JP7148604B2 (ja) | ＣＤＫ阻害剤としての４－［［（７－アミノピラゾロ［１，５－ａ］ピリミジン－５－イル）アミノ］メチル］ピペリジン－３－オール化合物 | |
| JP2008540554A5 (enExample) | ||
| JP2015531764A5 (enExample) | ||
| JP5203712B2 (ja) | 選択的アンドロゲン受容体モジュレータとしてのアミノフェニル誘導体 | |
| JP2018184452A (ja) | 置換アシルアニリドおよびそれらの使用方法 | |
| JP2006518328A5 (enExample) | ||
| JP2006514098A5 (enExample) | ||
| CA2918284A1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| JP2017128612A (ja) | Ａｒｒｙ−３８０の多形体、選択的ｅｒｂｂ２（ｈｅｒ２）阻害剤、およびそれらを含有する薬学的組成物 | |
| JP2018502867A5 (enExample) | ||
| JP2017516806A (ja) | 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体 | |
| EP3440081A1 (en) | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| JP2016525142A5 (enExample) | ||
| JP2015536997A5 (enExample) | ||
| JP2019525955A (ja) | 新規化合物およびその使用 | |
| JP2008531558A5 (enExample) | ||
| US20170001988A1 (en) | Piperidine and piperazine derivatives and their use in treating viral infections and cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100901 |